AA
SBBP

ALPS Advisors’s Strongbridge Biopharma plc. SBBP Stock Holding History

ALPS Advisors’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-82,657
Closed -$401K – 977
2018
Q3 		$401K Buy
82,657
+16,574
+25% +$84.8K ﹤0.01% 878
2018
Q2 		$396K Buy
+66,083
New +$483K ﹤0.01% 774

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ALPS Advisors's SBBP Position: Q4 2018 in Review

ALPS Advisors sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2018, closing a stake of 82,657 shares — an estimated $401K sold.

ALPS Advisors first reported a position in SBBP in Q2 2018 and held it in 2 quarters. The position peaked at $401K in Q3 2018. 42 funds tracked by Wall St. Rank hold SBBP as of Q4 2018.

  • ALPS Advisors reported no remaining Strongbridge Biopharma plc. position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 82,657 Strongbridge Biopharma plc. shares in Q4 2018, an estimated $401K.
  • ALPS Advisors first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 2 quarters.
  • ALPS Advisors's Strongbridge Biopharma plc. position peaked at $401K in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.